|
Call for Abstracts | Program Committee | Program | Posters | Invited Speakers
2010 Paty Lecture | Registration & Housing | Info for Presenters | 2010 Awards
CME Approval | Commercial Support
 CME SPONSORSHIP
This educational activity is jointly sponsored by the University of Maryland School of Medicine and the Americas Committee for Treatment and Research in Multiple Sclerosis.
OVERVIEW
Drug therapies presently available for treatment of multiple sclerosis (MS) slow the progression of the disease but do not cure it. Present therapies are relatively safe, but are only partially effective. Therapies in the pipeline promise to be more effective, but will carry greater risk. As the range of therapies grows, clinicians need to have an understanding of how new treatments are evaluated, used, and monitored so that they can better help their patients evaluate the relative risks and benefits of all available treatments.
TARGET AUDIENCE
This educational activity is intended for clinicians, clinical investigators, basic scientists and other healthcare professionals with an interest in multiple sclerosis and other demyelinating diseases.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Describe the current state of MS research regarding stem cell therapy and endogenous repair
- Discuss with patients the benefits and risks of different treatments
- Describe possible complications from immunosuppressive/immune-modifying therapies
- Recognize clinical features of PML
ACCREDITATION
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Maryland School of Medicine and the America’s Committee for Treatment and Research in Multiple Sclerosis. The University of Maryland School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
The University of Maryland School of Medicine designates this educational activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
DISCLOSURE
It is the policy of the University of Maryland School of Medicine to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, all persons in a position to control activity content of this continuing medical education activity will disclose the existence or non-existence of financial relationships with commercial interests relevant to activity content in educational materials distributed to participants prior to the activity. Any conflicts of interest identified will be resolved prior to presentation of the educational activity.
DISCUSSION OF OFF-LABEL OR INVESTIGATIONAL USES
Presentations in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. The audience is advised to consult the full prescribing information of all drugs or devices prior to use. Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with the applicable law.
UMSOM requires that all contributors disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.
DISCLAIMER
This CME activity is designed for use by healthcare professionals for educational purposes only. Information and opinions offered by the contributors represent their viewpoints. Conclusions drawn by the participant should be derived from careful consideration of all available scientific information. Prescription information and use of medical devices should be undertaken only after confirmation of information by consulting the FDA-approved uses and information.
While UMSOM makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others.
ACKNOWLEDGEMENT OF SUPPORT
Institutions, organizations, and/or companies providing educational grants in support of ACTRIMS will be acknowledged in educational materials provided to participants prior to the activity.
|
